Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30 2022 - 5:00PM
Pyxis Oncology, Inc. (Nasdaq: PYXS), a diversified oncology company
focused on developing an arsenal of next-generation therapeutics to
target difficult-to-treat cancers and improve quality of life for
patients, reported on September 30, 2022 that Pyxis Oncology’s
Compensation Committee of the Board of Directors granted restricted
stock units with respect to an aggregate of 213,030 shares of Pyxis
Oncology’s common stock and stock options to purchase an aggregate
of 266,290 shares of Pyxis Oncology’s common stock to seventeen
newly hired employees. The awards were granted under the Pyxis
Oncology, Inc. 2022 Inducement Plan with a grant date of September
30, 2022, as an inducement material to the new employee entering
employment with Pyxis Oncology, in accordance with Nasdaq Listing
Rule 5635(c)(4).
The restricted stock units and stock options vest over four
years, with 25% vesting on the first anniversary of the vesting
commencement date for each employee and the remaining shares
vesting monthly over the 36-month period thereafter, subject to
continued employment with the Company through the applicable
vesting dates. The stock options have a ten-year term and an
exercise price of $1.97, the closing price of Pyxis Oncology’s
common stock as reported by Nasdaq on September 30, 2022.
Pyxis Oncology is providing this information in accordance with
Nasdaq Listing Rule 5635(c)(4).
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is an oncology company focused on
developing an arsenal of next-generation therapeutics to target
difficult-to-treat cancers and improve quality of life for
patients. By leveraging our fully integrated research, development
and commercial capabilities, our expert team is efficiently
building a diversified portfolio of next-generation therapeutics.
Pyxis Oncology’s therapeutic candidates are designed to directly
kill tumor cells, and to address the underlying pathologies created
by cancer that enable its uncontrollable proliferation and immune
evasion. Since its launch in 2019, Pyxis Oncology has developed a
broad portfolio of novel antibody-drug conjugate, or ADC,
immuno-oncology, or IO, product candidates, and monoclonal
antibody, or mAb, preclinical discovery programs that it is
developing as monotherapies and in combination with other
therapies. To learn more about Pyxis Oncology, visit
www.pyxisoncology.com.
Pyxis Oncology ContactPamela ConnealyChief
Financial Officer(617) 453-3596ir@pyxisoncology.com
Pyxis Oncology (NASDAQ:PYXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pyxis Oncology (NASDAQ:PYXS)
Historical Stock Chart
From Apr 2023 to Apr 2024